Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.36 |
| ▸ | FABP7 | O15540 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798802 | 0.87 | SMN1; SMN2 (0.38) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL3303401 | 0.87 | PTGS2 (0.36) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL4799109 | 0.85 | ACE (0.37) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL3310057 | 0.85 | FKBP1A (0.42) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL4799791 | 0.83 | ACE (0.42) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL29634854 | 0.82 | ACE (0.45) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL17356388 | 0.82 | ACE (0.45) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL22648502 | 0.82 | ACE (0.45) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL3308417 | 0.82 | ACE (0.45) | FABP5FABP7KMT2AACEMEN1 | |
| SCHEMBL28777376 | 0.82 | ACE (0.45) | FABP5FABP7KMT2AACEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125695-B1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2016-10-26 | — | — | EP | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | FABP5 3689/4885FABP7 2520/4885KMT2A 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.